Prospective study evaluates long-term efficacy and safety of abrocitinib with UVB therapy in non-segmental vitiligo, highlighting its potential as an effective treatment.
Background Janus kinase (JAK) inhibitors, such as abrocitinib, are emerging alternatives to glucocorticoids for treating progressive non-segmental vitiligo (NSV), though long-term data remain limited.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: